Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of arguably the most economically important global swine disease. The extensive genetic variation of PRRSV strains is a major obstacle for heterologous protection of current vaccines. Previously, we constructed a panel of chimeric viruses containing only the ectodomain sequences of DNA-shuffled structural genes of different PRRSV strains in the backbone of a commercial vaccine, and found that one chimeric virus had an improved cross-protection efficacy. In this present study, to further enhance the cross-protective efficacy against heterologous strains, we constructed a novel chimeric virus VR2385-S3456 containing the full-length sequences of shuffled structural genes (ORFs 3-6) from 6 heterologous PRRSV strains in the backbone of PRRSV strain VR2385. We showed that the chimeric virus VR2385-S3456 induced a high level of neutralizing antibodies in pigs against two heterologous strains. A subsequent vaccination and challenge study in 48 pigs revealed that the chimeric virus VR2385-S3456 conferred an enhanced cross-protection when challenged with heterologous virus strain NADC20 or a contemporary heterologous strain RFLP 1-7-4. The results suggest that the chimera VR2385-S3456 may be a good PRRSV vaccine candidate for further development to confer heterologous protection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2427-2434 |
| Number of pages | 8 |
| Journal | Vaccine |
| Volume | 35 |
| Issue number | 18 |
| DOIs | |
| State | Published - Apr 25 2017 |
Fingerprint
Keywords
- Cross-protection
- DNA shuffling
- Heterologous strains
- Porcine reproductive and respiratory syndrome virus (PRRSV)
- RFLP 1-7-4
- Vaccine
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Cite this
Enhancing heterologous protection in pigs vaccinated with chimeric porcine reproductive and respiratory syndrome virus containing the full-length sequences of shuffled structural genes of multiple heterologous strains. / Tian, Debin; Cao, Dianjun; Lynn Heffron, C.; Yugo, Danielle M.; Rogers, Adam J.; Overend, Christopher; Matzinger, Shannon R.; Subramaniam, Sakthivel; Opriessnig, Tanja; LeRoith, Tanya; Meng, Xiang Jin.
In: Vaccine, Vol. 35, No. 18, 25.04.2017, p. 2427-2434.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Enhancing heterologous protection in pigs vaccinated with chimeric porcine reproductive and respiratory syndrome virus containing the full-length sequences of shuffled structural genes of multiple heterologous strains
AU - Tian, Debin
AU - Cao, Dianjun
AU - Lynn Heffron, C.
AU - Yugo, Danielle M.
AU - Rogers, Adam J.
AU - Overend, Christopher
AU - Matzinger, Shannon R.
AU - Subramaniam, Sakthivel
AU - Opriessnig, Tanja
AU - LeRoith, Tanya
AU - Meng, Xiang Jin
PY - 2017/4/25
Y1 - 2017/4/25
N2 - Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of arguably the most economically important global swine disease. The extensive genetic variation of PRRSV strains is a major obstacle for heterologous protection of current vaccines. Previously, we constructed a panel of chimeric viruses containing only the ectodomain sequences of DNA-shuffled structural genes of different PRRSV strains in the backbone of a commercial vaccine, and found that one chimeric virus had an improved cross-protection efficacy. In this present study, to further enhance the cross-protective efficacy against heterologous strains, we constructed a novel chimeric virus VR2385-S3456 containing the full-length sequences of shuffled structural genes (ORFs 3-6) from 6 heterologous PRRSV strains in the backbone of PRRSV strain VR2385. We showed that the chimeric virus VR2385-S3456 induced a high level of neutralizing antibodies in pigs against two heterologous strains. A subsequent vaccination and challenge study in 48 pigs revealed that the chimeric virus VR2385-S3456 conferred an enhanced cross-protection when challenged with heterologous virus strain NADC20 or a contemporary heterologous strain RFLP 1-7-4. The results suggest that the chimera VR2385-S3456 may be a good PRRSV vaccine candidate for further development to confer heterologous protection.
AB - Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of arguably the most economically important global swine disease. The extensive genetic variation of PRRSV strains is a major obstacle for heterologous protection of current vaccines. Previously, we constructed a panel of chimeric viruses containing only the ectodomain sequences of DNA-shuffled structural genes of different PRRSV strains in the backbone of a commercial vaccine, and found that one chimeric virus had an improved cross-protection efficacy. In this present study, to further enhance the cross-protective efficacy against heterologous strains, we constructed a novel chimeric virus VR2385-S3456 containing the full-length sequences of shuffled structural genes (ORFs 3-6) from 6 heterologous PRRSV strains in the backbone of PRRSV strain VR2385. We showed that the chimeric virus VR2385-S3456 induced a high level of neutralizing antibodies in pigs against two heterologous strains. A subsequent vaccination and challenge study in 48 pigs revealed that the chimeric virus VR2385-S3456 conferred an enhanced cross-protection when challenged with heterologous virus strain NADC20 or a contemporary heterologous strain RFLP 1-7-4. The results suggest that the chimera VR2385-S3456 may be a good PRRSV vaccine candidate for further development to confer heterologous protection.
KW - Cross-protection
KW - DNA shuffling
KW - Heterologous strains
KW - Porcine reproductive and respiratory syndrome virus (PRRSV)
KW - RFLP 1-7-4
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85016068524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016068524&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2017.03.046
DO - 10.1016/j.vaccine.2017.03.046
M3 - Article
AN - SCOPUS:85016068524
VL - 35
SP - 2427
EP - 2434
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 18
ER -